行情

SBBP

SBBP

Strongbridge
NASDAQ

实时行情|Nasdaq Last Sale

1.960
-0.020
-1.01%
交易中 15:11 10/15 EDT
开盘
1.980
昨收
1.980
最高
2.000
最低
1.930
成交量
15.38万
成交额
--
52周最高
6.52
52周最低
1.930
市值
1.06亿
市盈率(TTM)
2.578
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SBBP 新闻

  • 邓普顿基金明星经理失手 旗舰债基三个月亏30亿美元
  • 新浪美股.53分钟前
  • 一文看懂谷歌秋季发布会:AI串联全家桶
  • 新浪科技.1小时前
  • 高盛表示已将持有的WeWork股权减记了8000万美元
  • 新浪美股.1小时前
  • 德国警告英国脱欧将推迟 协议不足以解决技术性问题
  • 新浪美股.2小时前

更多

所属板块

制药
+1.12%
制药与医学研究
+1.27%

热门股票

名称
价格
涨跌幅

SBBP 简况

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
展开

Webull提供Strongbridge Biopharma plc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。